Zobrazeno 1 - 10
of 246
pro vyhledávání: '"David, Pérol"'
Autor:
Armelle Dufresne, Valéry Attignon, Anthony Ferrari, Laurie Tonon, Sandrine Boyault, Séverine Tabone‐Eglinger, Philippe Cassier, Olivier Trédan, Nadège Corradini, Armelle Vinceneux, Aurélie Swalduz, Alain Viari, Sylvie Chabaud, David Pérol, Jean Yves Blay, Pierre Saintigny
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction The objective was to determine the added value of comprehensive molecular profile by whole‐exome and RNA sequencing (WES/RNA‐Seq) in advanced and refractory cancer patients who had no molecular‐based treatment recommendati
Externí odkaz:
https://doaj.org/article/9b729f0973334b92809d58a905b67735
Autor:
Coralie Courtinard, Sophie Gourgou, William Jacot, Matthieu Carton, Olivier Guérin, Laure Vacher, Aurélie Bertaut, Marie-Cécile Le Deley, David Pérol, Patricia Marino, Christelle Levy, Lionel Uwer, Geneviève Perrocheau, Renaud Schiappa, Florence Bachelot, Damien Parent, Mathias Breton, Thierry Petit, Thomas Filleron, Agnès Loeb, Simone Mathoulin Pélissier, Mathieu Robain, Suzette Delaloge, Carine Bellera
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence
Externí odkaz:
https://doaj.org/article/95e587a2739d4813945eb54f7074bcab
Autor:
Nour‐El‐Houda Mourksi, Cécile Dalban, Amélie Colombe‐Vermorel, Laetitia Odeyer, Valentin Simioni, Jean‐Sébastien Frenel, Michel Fabbro, Fernando Bazan, Sophie Abadie‐Lacourtoisie, Elodie Coquan, Séverine Martinez, Gwenaelle Garin, Séverine Tabone‐Eglinger, Isabelle Treilleux, Sylvie Chabaud, David Pérol, Isabelle Ray‐Coquard, Pierre‐Etienne Heudel, Jean‐Jacques Diaz, Virginie Marcel
Publikováno v:
Molecular Oncology, Vol 17, Iss 1, Pp 27-36 (2023)
Resistance of advanced hormone‐dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves t
Externí odkaz:
https://doaj.org/article/ae737b53e2ab4d899bf43ee577ab684b
Autor:
Séverine Racadot, Antoine Arnaud, Camille Schiffler, Séverine Metzger, David Pérol, Youlia Kirova
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 41, Iss , Pp 100647- (2023)
Background and purpose: To prevent the occurrence of grade ≥ 2 radiodermatitis after post-operative breast irradiation in patients with non metastatic breast cancer. Methods: This prospective randomised open-label multicenter study allocated patien
Externí odkaz:
https://doaj.org/article/0cb2a3063f8a4be6bdc53ae5ced1956b
Autor:
Flora Nguyen Van Long, Audrey Lardy-Cleaud, Dimitri Carène, Caroline Rossoni, Frédéric Catez, Paul Rollet, Nathalie Pion, Déborah Monchiet, Agathe Dolbeau, Marjorie Martin, Valentin Simioni, Susan Bray, Doris Le Beherec, Fernanda Mosele, Ibrahim Bouakka, Amélie Colombe-Vermorel, Laetitia Odeyer, Alexandra Diot, Lee B. Jordan, Alastair M. Thompson, Françoise Jamen, Thierry Dubois, Sylvie Chabaud, Stefan Michiels, Isabelle Treilleux, Jean-Christophe Bourdon, David Pérol, Alain Puisieux, Fabrice André, Jean-Jacques Diaz, Virginie Marcel
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background A current critical need remains in the identification of prognostic and predictive markers in early breast cancer. It appears that a distinctive trait of cancer cells is their addiction to hyperactivation of ribosome biogenesis. T
Externí odkaz:
https://doaj.org/article/fb1de5e1e47048e5883db9d402d40dd4
Autor:
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, Isabelle Ray-Coquard, Christelle De La Fouchardière, François Bertucci, Anthony Gonçalves, Carlos Gomez-Roca, Benoit You, Valéry Attignon, Sandrine Boyault, Philippe A. Cassier, Armelle Dufresne, Séverine Tabone-Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenaël Garin, Jean-Yves Blay, David Pérol
Publikováno v:
Cancers, Vol 15, Iss 13, p 3441 (2023)
Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on patients with
Externí odkaz:
https://doaj.org/article/9252af336131459388bd3c930b52ed6c
Autor:
Pierre Leblond, Maura Massimino, Martin English, Timothy A. Ritzmann, Lorenza Gandola, Gabriele Calaminus, Sophie Thomas, David Pérol, Julien Gautier, Richard G. Grundy, Didier Frappaz
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
Background:The clinical management of ependymoma in childhood and adolescence is complex and the clinicobiopathological correlates of outcome remain poorly understood. This international SIOP Ependymoma II (SIOP EPII) trial aims to improve the outcom
Externí odkaz:
https://doaj.org/article/039c66c91b954e1c9e916cc62b281ca6
Autor:
Philippe A. Cassier, Clémentine Peyramaure, Valery Attignon, Lauriane Eberst, Camille Pacaud, Sandrine Boyault, Françoise Desseigne, Mathieu Sarabi, Pierre Guibert, Pauline Rochefort, Nathalie Marques, Michel Rivoire, Aurélien Dupré, Patrice Peyrat, Catherine Terret, Isabelle Ray-Coquard, Clélia Coutzac, David Pérol, Jean-Yves Blay, Olivier Trédan, Christelle de la Fouchardière
Publikováno v:
Translational Oncology, Vol 15, Iss 1, Pp 101266- (2022)
Background: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents. Methods: In this report we describe the mutational landscape and outcome of patients with gast
Externí odkaz:
https://doaj.org/article/af51f8a698dc4ce7a25e81ac463e3700
Autor:
Pierre-Alexandre Squara, Vinh-Phuc Luu, David Pérol, Bruno Coudert, Valérie Machuron, Camille Bachot, Laurence Samelson, Virginie Florentin, Jean-Marc Pinguet, Béchir Ben Hadj Yahia
Publikováno v:
PLoS ONE, Vol 17, Iss 4, p e0267242 (2022)
ObjectiveThis article describes the Personalized Reimbursement Model (PRM) program methodology, limitations, achievement and perspectives in using real-world data of cancer drugs use to improve and personalize drug pricing and reimbursement in France
Externí odkaz:
https://doaj.org/article/6bbb1b8c7b934356810899e36ddbd271
Autor:
Lidia Delrieu, Amélie Anota, Olivier Trédan, Damien Freyssenet, Aurélia Maire, Brice Canada, Baptiste Fournier, Olivia Febvey-Combes, Frank Pilleul, Amine Bouhamama, Christophe Caux, Florence Joly, Béatrice Fervers, Vincent Pialoux, David Pérol, Olivia Pérol
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Patients with a metastatic breast cancer suffer from a deteriorated health-related quality of life and numerous symptoms such as pain, severe fatigue and a decrease of their physical fitness. As the feasibility of a physical activ
Externí odkaz:
https://doaj.org/article/05bc1d2c94424bbeb97d6ef3f5e60443